Analyst Price Targets — BIIB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 9:20 pm | Emily Field | Barclays | $185.00 | $192.08 | TheFly | Biogen initiated with an Equal Weight at Barclays |
| February 11, 2026 12:51 pm | — | Mizuho Securities | $236.00 | $188.99 | TheFly | Biogen price target raised to $236 from $207 at Mizuho |
| February 10, 2026 1:21 pm | Laura Chico | Wedbush | $187.00 | $192.72 | TheFly | Biogen price target raised to $187 from $178 at Wedbush |
| February 9, 2026 2:46 pm | — | Wolfe Research | $231.00 | $196.00 | StreetInsider | Goldman Sachs Reiterates Buy Rating on Biogen (BIIB) |
| February 9, 2026 2:43 pm | — | RBC Capital | $233.00 | $195.93 | TheFly | Biogen price target raised to $233 from $217 at RBC Capital |
| February 9, 2026 2:25 pm | — | Wolfe Research | $215.00 | $195.45 | StreetInsider | Biogen (BIIB) PT Raised to $215 at TD Cowen |
| February 9, 2026 12:23 pm | Danielle Brill | Truist Financial | $193.00 | $201.18 | TheFly | Biogen price target raised to $193 from $190 at Truist |
| February 9, 2026 12:06 pm | — | Canaccord Genuity | $230.00 | $201.18 | TheFly | Biogen price target raised to $230 from $220 at Canaccord |
| February 9, 2026 12:02 pm | — | Piper Sandler | $177.00 | $201.18 | TheFly | Biogen price target raised to $177 from $157 at Piper Sandler |
| February 9, 2026 11:45 am | Yatin Suneja | Guggenheim | $246.00 | $201.18 | TheFly | Biogen price target raised to $246 from $185 at Guggenheim |
Latest News for BIIB
Fisher Asset Management LLC reduced its stake in Biogen Inc. (NASDAQ: BIIB) by 4.1% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 277,285 shares of the biotechnology company's stock after selling 11,852 shares during the quarter. Fisher Asset
Biogen Inc. (BIIB) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Shares of Biogen Inc. (NASDAQ: BIIB - Get Free Report) have earned an average recommendation of "Hold" from the twenty-seven brokerages that are covering the stock, MarketBeat Ratings reports. Fifteen research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average twelve-month price target among
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
China Universal Asset Management Co. Ltd. lessened its holdings in Biogen Inc. (NASDAQ: BIIB) by 9.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,570 shares of the biotechnology company's stock after selling 3,187 shares during the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.